期刊文献+

帕金森病患者膀胱过动症状评估 被引量:5

Assessment of concomitant overactive bladder symptoms in Parkinson disease
下载PDF
导出
摘要 目的分析PD患者膀胱过动症状(OABS)的患病率、影响因素以及OABS对PD患者生活质量(health related quality of life,HRQL)的影响。方法运用膀胱过度活动症问卷(overactive bladder question-naire,OAB-q)、统一帕金森病评分量表(UPDRS)对115例PD患者进行评估。结果 PD患者OABS患病率47.0%。PD组OABSS得分明显高于对照组(P=0.000);PD组的生活质量得分均低于对照组。年龄及帕金森病严重程度与PD患者OABS严重程度呈正相关。OAB组HRQL得分较非OAB组低(P=0.003)。结论 OABS是PD患者中常见的非运动症状之一,OABS严重影响PD患者生活质量,年龄增长和PD病情恶化可增加OABS的严重程度。 Objective To analyze the prevalence and impact factors of overactive bladder symptoms(OABS) and the OABS influence on health related quality of life(HRQL) in patients with Parkinson disease(PD).Methods The overactive bladder questionnaire(OAB-q) and unified Parkinson disease rating scale(UPDRS) were used to evaluate 115 patients with idiopathic PD.The results were taken from PD patients and compared with those of 123 control subjects.Results The prevalence of OABS in PD patients was 47.0%.Compared with the control subjects,PD patients had higher overactive bladder symptom severity(OABSS) score(P=0.000) and lower HRQL score.PD patients with OABS were lower in HRQL score than PD patients without OABS(P=0.003).The age and severity of PD were the impact factors of OABS.Conclusions OABS is a kind of common symptom in PD patients,which influenced the HRQL of PD patients seriously.OABS will be worse when the PD patients are older and PD is aggravated.
出处 《中国神经免疫学和神经病学杂志》 CAS 北大核心 2012年第5期346-348,353,共4页 Chinese Journal of Neuroimmunology and Neurology
基金 国家自然科学基金资助项目(81071025 81171203 81171204) 上海市科技委员会基金资助项目(11nm0503300 11410708900 12XD1403800) 上海市教育委员会资助项目(10ZZ72)
关键词 帕金森病 膀胱过动症状 生活质量 影响因素 Parkinson disease overactive bladder symptoms health related quality of life impact factors
  • 相关文献

参考文献13

  • 1Verbaan D, Marinus J, Visser M, et al. Patient-reported autonomic symptoms in Parkinson disease [J]. Neurology, 2007,69: 333-341.
  • 2干静,周明珠,刘振国,陈伟,陆丽霞,吴佳英.帕金森病患者自主神经功能障碍评估[J].中国临床神经科学,2008,16(3):251-256. 被引量:14
  • 3Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score [J]. J Neurology Neurosurg Psychiatry, 2000,68 : 429-33.
  • 4Campos-Sousa RN, Quagliato E, da Silva BB, et al. Urinary symptoms in Parkinson's disease: prevalence and associated factors[J]. Arq Neuropsiquiatr, 2003,61: 359-363.
  • 5Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ, et al. Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson s disease:target related effect or selection bias? [J]. J Neurol Neurosurg Psychiatry, 2005,76 : 34-39.
  • 6Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson' s disease[J]. J Neurol Neurosurg Psychiatry, 1988,51 : 745-752.
  • 7Irwin DE. Abrams P, Milsom I, et al. Understanding the elements of overactive bladder questions raised by the EPIC study[J]. BJU Int, 2008,101 (11): 1381-1387.
  • 8Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q[J]. Qual Life Res, 2002, 11:563-574.
  • 9Chapple CR. Primer: questionnaires versus urodynamics in the evaluation of lower urinary tract dysfunctlon-one, both or none? [J]. Nat Clin Pract Urol,2005,2: 555-564.
  • 10Carbone A, Palleschi G, Conte A, et al. Gabapentin treatment of neurogenic overactive bladder[J]. Clin Neuropharmacol, 2006,29: 206-214.

二级参考文献18

  • 1Verbaan D, Marinus J, Visser M, et al. Patient-reported autonomic symptoms in Parkinson disease[J]. Neurology, 2007,69:333-341.
  • 2Visser M, Marinus J, Stiggelbout AM, et al. Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA-AUT[J]. Mov Disord,2004,19:1306-1312.
  • 3Jost WH. Autonomic dysfunction in idiopathic Parkinson 's disease [J]. J Neurol, 2003,250(suppl 1):I28-I30.
  • 4Siddiqui MF, Rast S, Lynn MJ, et al. Autonomic dysfunction in Parkinson's disease:a comprehensive symptom survey[J]. Parkinsonism Relat Disord, 2002,8:277-284.
  • 5Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease[J]. J Neurol Neurosurg Psychiatry, 1988,51: 745-752.
  • 6Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ, et al. Different patterns of medication change after subthalamic or pallidal stimu- lation for Parkinson's disease: target related effect or selection bias? [J]. J Neurol Neurosurg Psychiatry, 2005,76:34-39.
  • 7Gan J, Xie-Brustolin J,Mertens P,et al. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: three years follow-up [J]. J Neurol, 2007,2541:99-106.
  • 8Fahn S, Elton R and Members of the UPDRS Development Committee(Jankovic J). Unified Parkinson's disease rating scale [M]. In:Recent Developments in Parkinson's Disease, MacMillan Healthcare Information, Flonham Park, N J, 1987,11:153-163.
  • 9Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease[J]. Alzheimer Dis Assoc Disord. 1997,11(suppl 2):S33-S39.
  • 10Hamilton M. A rating scale for depression[J]. J Neurol Neurosurg Psychiatry,1960, 23:56-62.

共引文献13

同被引文献45

  • 1杨尚琪,来永庆,陈月英,池泽湃,任瑞,王亚东,魏灿,倪梁朝,关志忱.膀胱过度活动症症状评分表评估膀胱过度活动症的临床研究[J].中华临床医师杂志(电子版),2012,6(16):4675-4678. 被引量:25
  • 2Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol, 2009, 8: 1158-1171.
  • 3Chanci P. Advances in the medical treatment ofParkinson's disease. Parkinsonism Relat Disord, 2009, 15 Suppl 3: $22-25.
  • 4Tsang KL, Chi I, Ho SL, et al. Translation and validation of the standard Chinese version of PDQ- 39: a quality-of-life measure for patients with Parkinsons disease. Mov Disord, 2002, 17 1036 1040.
  • 5Luo N, Tan LC, Li SC, et al. Validity and reliability of Chinese (Singapore)Version of the Parkinson s disease Questionnaire (PDQ-39). Qual Life Res, 2005,14:273-279.
  • 6Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinsons disease? J Neurol Neurosurg Psychiatry, 2000, 69 : 308-312.
  • 7Shulman LM, Taback RL, Rabinstein AA, et al. Non-recognition of depression and other non- motor symptoms in Parkinsonrs disease. Parkinsonism Relat Disord, 2002, 8..193-197.
  • 8Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. Predictors and course of health-related quality of life in Parkinsonrs disease. Mov Disord, 2008,23.. 1420- 1427.
  • 9I Brown RG, Maccarthy B, Gothman AM, et al. Depression and disability in Parkinsonr s disease : a follow-up of 132 cases. Psychol Med, 1988, 18: 49- 55.
  • 10Rampello L, Chiechio R, Raffaele R, et al. The SSRI, citalopram, improves bradykinesia in patients with Parkinsonrs disease treated with L-dopa. Clin Neuropharmacol, 2002, 25: 21-24.

引证文献5

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部